Research location
Corvallis
Oregon, United States
Advertisement
Research activity in Corvallis
Oregon, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 133 trials and 135 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Corvallis
133 linked trials · page 1 of 3A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579 · 2026-08-26 · 1 site observation
RECRUITING
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body WeightNCT07770841 · 2026-08-12 · 1 site observation
RECRUITING
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22 · 1 site observation
RECRUITING
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)NCT07221474 · 2025-12-12 · 1 site observation
RECRUITING
Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer SurvivorsNCT07055854 · 2025-09-30 · 1 site observation
RECRUITING
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21 · 1 site observation
RECRUITING
Phase IIIb Study of Ribociclib + ET in Early Breast CancerNCT05827081 · 2024-02-28 · 1 site observation
RECRUITING
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)NCT06170788 · 2023-12-15 · 1 site observation
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation
RECRUITING
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])NCT04267848 · 2020-06-16 · 1 site observation
RECRUITING
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeNCT03191149 · 2018-04-25 · 1 site observation
RECRUITING
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesNCT06972472 · 2025-05-19 · 1 site observation
ACTIVE_NOT_RECRUITING
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792 · 2025-05-15 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459 · 2025-05-15 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722 · 2024-02-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)NCT06077760 · 2023-12-06 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT06045221 · 2023-09-22 · 1 site observation
COMPLETED
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940 · 2023-08-09 · 1 site observation
COMPLETED
Use of Empagliflozin to Treat PrediabetesNCT05426525 · 2022-10-13 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512 · 2022-10-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 DiabetesNCT05433584 · 2022-08-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Opening the Conversation StudyNCT04806724 · 2021-09-01 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are OverweightNCT04657003 · 2021-03-29 · 1 site observation
COMPLETED
Insulin and Muscle Fat MetabolismNCT04759872 · 2021-02-22 · 1 site observation
TERMINATED
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypeNCT04718389 · 2021-01-26 · 1 site observation
COMPLETED
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 DiabetesNCT04707469 · 2021-01-15 · 1 site observation
COMPLETED
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung CancerNCT04533451 · 2020-11-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)NCT04496739 · 2020-10-23 · 1 site observation
ACTIVE_NOT_RECRUITING
GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot StudyNCT04473274 · 2020-05-21 · 1 site observation
COMPLETED
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerNCT04092283 · 2020-04-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Baricitinib in Participants With Rheumatoid ArthritisNCT04086745 · 2020-02-14 · 1 site observation
COMPLETED
House Dust Mite Allergy Trial In ChildrenNCT04145219 · 2019-10-12 · 1 site observation
COMPLETED
Mitochondrial Remodeling After ExerciseNCT04103424 · 2019-08-23 · 1 site observation
COMPLETED
Mindful After Cancer: A Mindfulness-based Therapy Intervention for Sexual Health After CancerNCT04559854 · 2019-07-01 · 1 site observation
COMPLETED
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 DiabetesNCT03989232 · 2019-06-19 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AloneNCT03954834 · 2019-06-03 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 DiabetesNCT03882970 · 2019-04-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)NCT03829319 · 2019-03-25 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular RiskNCT03730662 · 2018-11-20 · 1 site observation
COMPLETED
A Study of LY3209590 in Participants With Type 2 Diabetes MellitusNCT03736785 · 2018-11-15 · 1 site observation
COMPLETED
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · 2018-10-24 · 1 site observation
COMPLETED
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerNCT03488693 · 2018-10-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 DiabetesNCT03495102 · 2018-04-05 · 1 site observation
COMPLETED
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)NCT03373045 · 2018-02-27 · 1 site observation
COMPLETED
A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.NCT03281876 · 2017-11-27 · 1 site observation
COMPLETED
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF PatientsNCT03066804 · 2017-08-22 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes MellitusNCT03131687 · 2017-05-24 · 1 site observation
COMPLETED
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerNCT03137771 · 2017-04-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.